[Dendrite cell-based cancer vaccines--clinical application].
Dendritic cell (DC)-based vaccination against cancer is a specific immunotherapy with a new therapeutic approach for patients with cancer. Preclinical and clinical trials, in which more than 1,000 cancer patients received dendritic cell vaccination, have shown that it is possible to activate the immune system against cancer cells and to induce a clinical response in some of the patients. The treatment is so far experimental, and there is a need for well-designed trials that aim to improve the DC vaccine approach.
Svane
Inge Marie
IM
Amtssygehuset i Herlev, Onkologisk og Haematologisk Afdeling, og Københavns Universitet, Panum Instituttet, Herlev. inge.m.svane@dadlnet.dk
Berntsen
Annika
A
Trepiakas
Redas
R
Pedersen
Anders Elm
AE
D019496:Cancer Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D003713:Dendritic Cells / Q000276:immunology; D005260:Female; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology; D016896:Treatment Outcome
D019496:Cancer Vaccines